Hasil Pencarian  ::  Simpan CSV :: Kembali

"Akrilamida diketahui sebagai senyawa genotoksik yang ditemukan dalam sampel makanan kaya karbohidrat yang dipanggang dan digoreng oleh beberapa peneliti di Swedia. Akrilamida bukan suatu zat yang ditambahkan ke dalam makanan tetapi sebagai hasil reaksi antara asam amino dan gula sederhana pada temperatur tinggi. Pada penelitian ini dilakukan analisis akrilamida yang terdapat dalam crackers. Kondisi analisis menggunakan kolom C18 dengan campuran 3,5 mmol/L asam fosfat dalam asetonitril-air (5:95) sebagai fase gerak, laju alir 0,5 mL/menit dideteksi pada panjang gelombang 210 nm. Waktu retensi yang dibutuhkan oleh akrilamida adalah 5,6 menit. Kalibrasi dilakukan pada rentang konsentrasi 0,1 ? 1,4 mg/mL dan hasil menunjukkan linieritas yang baik (r=0,99996). Batas deteksi dan batas kuantitasi masing-masing adalah 0,01mg/mL dan 0,0432 mg/mL. Uji akurasi dengan menggunakan pelarut etanol dan diklormetan (1:15) menghasilkan persen perolehan kembali sebesar 89,39% dengan Deviasi Standar Relatif 1,57%. Dari enam sampel crackers, lima mengandung akrilamida dengan kadar masing-masing, yaitu 0,2808; 0,4556; 0,5103; 0,8494 dan 0,9371 mg/g.Kata kunci: akrilamida; Kromatografi cair kinerja tinggi; crackers; diklormetan"

"The knowledge, skills and guidance managers need to become true learning leaders. Now more than ever, a versatile, well-trained workforce is critical to an organization?s success. Written for managers from a wide range of functional areas, this book gives any manager responsible for training the tools to help employees learn more, perform better, and work smarter. This comprehensive, up-to-date guide targets the roles necessary to manage training and learning in an organization: champion, builder, performance consultant, supporter, administrator, and keeper of the budget. Filled with expert information and real-world scenarios, this new book uses diagrams, charts, exercises, and a collection of tools for training delivery to help managers anticipate and solve a broad range of training challenges?for their own departments or for the entire organization. How to Manage Training: Facilitating Workplace Learning for High Performance delivers the knowledge, skills, and guidance managers need to become true learning leaders. Readers will learn how toL ? Develop a sample business plan for training ? Deliver learning experiences in a wide range of formats ? Create programs for peer-to-peer assistance and collegial problem solving ? Foster coaching and mentoring in the workplace ? Promote learning and training opportunities at all levels in the organization. This is an ebook version of the AMA Self-Study course. If you want to take the course for credit you need to either purchase a hard copy of the course through amaselfstudy."

"Having this book on your bookshelf is like having an on-call business training department. Ultimate Basic Business Skills provides ready-to-present programs on the most critical front-line business skills every member of your organization needs basic training that is often ignored in favor of more specialized product or service training. This book offers learning professionals everything needed to quickly deploy a business boot camp, including lively, scripted, half-day programs in more than 20 individual topic areas. Subjects include both external and internal customer service, basic business skills, and training to help employees thrive in a professional business environment. All handouts, worksheets, assessments, and PowerPoint presentations are included, and can easily be customized for their intended audience."

"The proceedings of the 5th International Workshop on Parallel Tools for High Performance Computing provide an overview on supportive software tools and environments in the fields of system management, parallel debugging and performance analysis. In the pursuit to maintain exponential growth for the performance of high performance computers the HPC community is currently targeting exascale systems. The initial planning for exascale already started when the first petaflop system was delivered. Many challenges need to be addressed to reach the necessary performance. Scalability, energy efficiency and fault-tolerance need to be increased by orders of magnitude. The goal can only be achieved when advanced hardware is combined with a suitable software stack. In fact, the importance of software is rapidly growing. As a result, many international projects focus on the necessary software."

"This book presents the state-of-the-art in simulation on supercomputers. Leading researchers present results achieved on systems of the Gauss-Allianz, the association of High-Performance Computing centers in Germany. The reports cover all fields of computational science and engineering, ranging from CFD to Computational Physics and Biology to Computer Science, with a special emphasis on industrially relevant applications. Presenting results for large-scale parallel microprocessor-based systems and GPU and FPGA-supported systems, the book makes it possible to compare the performance levels and usability of various architectures. Its outstanding results in achieving the highest performance for production codes are of particular interest for both scientists and engineers. The book includes a wealth of color illustrations and tables."

"This proceedings volume contains a selection of papers presented at the Fourth International Conference on High performance scientific computing held at the Hanoi Institute of Mathematics, Vietnamese Academy of Science and Technology (VAST), March 2-6, 2009. The conference was organized by the Hanoi Institute of Mathematics, the Interdisciplinary Center for Scientific Computing (IWR), Heidelberg, and its Heidelberg Graduate School of Mathematical and Computational Methods for the Sciences, and Ho Chi Minh City University of Technology. The contributions cover the broad interdisciplinary spectrum of scientific computing and present recent advances in theory, development of methods, and applications in practice. Subjects covered are mathematical modelling, numerical simulation, methods for optimization and control, parallel computing, software development, applications of scientific computing in physics, mechanics, biology and medicine, engineering, hydrology problems, transport, communication networks, production scheduling, industrial and commercial problems."

"Contents : - Part I:Overview - High-Speed I/O Design and Test Review:From the Perspectives of Moore is Law and Multiple Gbps Data Rates - Part II:System Architecture and Performance - Transfer Functions for the Reference Clock Jitter in a Serial Link: Theory and Applications - Channel Compliance Testing Utilizing Novel Statistical Eye Methodology - Advances in High-Speed Design in Dispersively Attenuating Environments Such as Cables and Backplanes - Part III:Design Simulation and Modeling - Static Crosstalk Analysis - Modeling Loss and Jitter in High-Speed Serial Connects - Design and Modeling Methodology for High-Performance Power Distribution Systems - Source Synchronous Bus Design and Timing Analysis for High-Volume Manufacturable System Interconnects - Part IV:Design for High Performance - Eye Opening Techniques Enabled by Dispersion Compensation - Maximizing 10-Gbps Transmission Path Length in Copper Backplanes with and without Transceiver Technology - How to Make Optimal Use of Signal Conditioning in 40-Gbps Copper Interconnects - Design of a 6.25-Gbps Backplane SerDes with Top-Down Design Methodology - A Flexible Serial Link for 5-10 Gbps in Realistic Backplane Environments - Part V:Characterization and Test - Signal Integrity and Jitter:How to Measure Them Correctly - A Statistical and System Transfer Function Based Method for Jitter and Noise in Communication Design and Test - Total Jitter Measurement at Low Probability Levels,Using the Optimized BERT Scan Method - Comparison and Correlation of Signal-Integrity Measurement Techniques - Performance Evaluation of High-Speed Serial Links - Physical-Layer Design and Characterization of a 3.2 Gbps/Pair Memory Channel - Acronym Guide "

"Penelitian ini dilakukan untuk mengetahui apakah bioavailabilitas formulasi ibuprofen suppositoria 125 mg yang diproduksi oleh PT Kalbe Farma,Tbk. (Ibukal®) bioekivalen dengan produk yang sama dari komparatornya (Proris®). Parameter farmakokinetik yang dinilai dalam studi ini ialah luas daerah di bawah kurva kadar - waktu selama 10 jam (AUC0-t), luas daerah di bawah kurva kadar - waktu sampai waktu tak terhingga (AUC0-inf), kadar puncak (Cmax), dan waktu untuk mencapai kadar puncak (tmax). Penelitian ini menggunakan rancangan menyilang acak, tersamar tunggal yang mengikutsertakan 12 sukarelawan dewasa sehat. Sukarelawan dipuasakan semalam dan keesokan harinya diberi 1 suppositoria obat uji (produk PT.Kalbe-Farma) atau 1 suppositoria obat pembanding (produk komparatornya). Contoh darah diambil pada jam ke 0 (kontrol), 20 min; 40 min; 1; 1,5; 2; 2,5; 3; 4; 6; 8; dan 10 jam setelah pemberian obat. Setelah 1 minggu periode washout, prosedur ini diulang dengan memberikan obat pembandingnya. Kadar obat ditentukan dengan kromatografi cair kinerja tinggi dengan detektor ultraviolet. Pada penelitian bioavailabilitas ini, rerata (SD) AUC0-t, AUC0-inf, Cmax dan tmax dari obat uji masing-masing adalah 28,59(3,37) µg.jam.mL-1, 30,47(3,56) µg.jam.mL-1,8,24(1,44)µg/mL, dan 1,33(0,44) jam. Rerata (SD) AUC0-t, AUC0-inf, Cmax dan tmax dari obat pembanding masing-masing adalah 28,13(8,14) µg.jam.mL-1, 30,56(8,05) µg.jam.mL-1, 8,27(2,88) µg/mL, dan 1,79(0,33) jam. Rasio rerata geometrik obat uji terhadap obat pembandingnya ialah 104,38% untuk AUC0-t, 101,97% untuk AUC0-inf, dan 104,02% untuk Cmax, Nilai 90% confidence intervals(CI) nya ialah 90,38-120,54% untuk AUC0-t, 89,51-116,16% untuk AUC0-inf, dan 85,73-126,16% untuk Cmax. Tidak ada efek samping yang dijumpai dalam penelitian ini. Dari hasil penelitian ini disimpulkan bahwa Ibuprofen suppositoria 125 mg produksi PT. Kalbe Farma,Tbk. (Ibukal®) bioekuivalen dengan produk yang sama dari komparatornya (Proris®). (Med J Indones 2007; 16:181-6).

---

This study was aimed to investigate the bioequivalence of ibuprofen 125 mg suppository formulation (Ibukal®, test formulation from PT. Kalbe Farma, Tbk., Jakarta) and the ibuprofen suppository comparative formulation (Proris®, from PT. Pharos Indonesia, Jakarta) in 12 healthy volunteers. The pharmacokinetic parameters used in this study were the area under the concentration-time curve from time zero to hour 10 (AUC0-t), the area under the concentration-time curve from time zero to infinite (AUC0-inf), the maximum concentration (Cmax), and the time needed to reach the maximum concentration (tmax). The study was designed as a random cross-over fashion, single-blinded which included 12 healthy adult volunteers. The volunteers were fasted overnight and in the morning they received a suppository of the test drug (Ibukal®) or a suppository of the comparative drug (Proris®). Blood samples were withdrawn on hour 0 (control), 20 min; 40 min; 1; 1,5; 2; 2,5; 3; 4; 6; 8; and 10 time points after the administration of the drug. Following a wash-out period of 1 week, this procedure was repeated using the other drug. The serum concentration of the drug was determined by means of high-performance liquid chromatography with ultraviolet detection. The results of the study showed that, the mean (SD) of AUC0-t, AUC0-inf, Cmax and tmax of the test drug were, respectively, 28.59(3.37) µg.h.mL-1, 30.47(3.56) µg.h.mL-1, 8.24(1.44) µg/mL, and 1.33(0.44) h. The mean (SD) of AUC0-t, AUC0-inf, Cmax and tmax of the comparative drug were, respectively, 28.13(8.14) µg.h.mL-1, 30.56(8.05) µg.h.mL-1, 8.27(2.88) µg/mL, and 1.79(0.33) h. The geometric means ratio of the test to the comparative drug were 104.38% (CI 90%: 90.38-120.54%) for AUC0-t, 101.97% (CI 90%: 89.51-116.16%) for AUC0-inf, and 104.02% (CI 90%: 85.73-126.16%) for Cmax. There was no side effect of the drug detected in this study. From the results we can conclude that the 125 mg of ibuprofen suppository of PT Kalbe Farma, Tbk. (Ibukal®) is bioequivalent to that of the comparative drug (Proris®). (Med J Indones 2007; 16:181-6)"